Biotech Daily

Wednesday June 25, 2025

Daily news on ASX-listed biotechnology companies

*** ASX FLAT, BIOTECH DOWN: RESONANCE UP 12%; PROTEOMICS DOWN 9%**

*** QBIOTICS: 'TIGILANOL TIGLATE 8 OF 10 SARCOMA RESPONSES'**

*** SNOW CENTRE, BIOGRID, ARIDHIA FOR DIGITAL IMMUNOLOGY**

*** CLEO GRANTED US CANCER BIO-BANK ACCESS**

*** BLUECHIIP CREDITORS MEETING TO DECIDE FUTURE**

*** PERCHERON REQUESTS 'LICENCING TRANSACTION' TRADING HALT**

*** BLINKLAB PLEADS 'SCHULTZ, EXPECTED DATA' TO ASX 14% QUERY**

*** ADVANCE REDUCES TO 7% OF OSTEOPORE**

*** MARK KERR DILUTED TO 11% OF AVECHO**

*** MARK AZZI TAKES 14.4% OF NYRADA**

*** NAOMI LAWRIE REPLACES MACH7 CO SEC TONY PANTHER**

MARKET REPORT

The Australian stock market edged up 0.04 percent on Wednesday June 25, 2025, with the ASX200 up 3.7 points to 8,559.2 points.

Fourteen of the Biotech Daily Top 40 companies were up, 16 fell, nine traded unchanged and one was untraded.

Resonance was the best, up 0.4 cents or 11.8 percent to 3.8 cents, with 288,778 shares traded. EBR was up 7.5 percent; Curvebeam climbed 6.1 percent; Aroa rose 5.9 percent; Immutep improved 4.35 percent; Syntara was up 3.9 percent; Compumedics, Cyclopharm, Dimerix and Mesoblast rose two percent or more; Medadvisor and SDI were up more than one percent; with Clinuvel, Orthocell and Resmed up by less than one percent.

Proteomics led the falls, down three cents or nine percent to 30.5 cents, with 912,586 shares traded. Imugene lost 8.3 percent; both Atomo and Micro-X were down 6.25 percent; Optiscan and Prescient fell more than four percent; Botanix, Impedimed and Paradigm were down more than three percent; Medical Developments, Nanosonics and Polynovo shed more than two percent; Avita, Clarity and CSL were down more than one percent; with Cochlear, Emvision, Pro Medicus and Telix down by less than one percent.

QBIOTICS

Qbiotics says its 11-patient, phase IIa trial shows tigilanol tiglate led to eight of 10 evaluable soft tissue sarcoma patients having an objective response.

Qbiotics said an objective response was either complete ablation, or a 100 percent reduction in volume, or a partial ablation, a 30 percent or more reduction in volume of treated tumors.

The company said 22 of the 27 injected tumors (81.5%) had a complete or partial ablation, with 14 demonstrating complete ablation and eight showing partial ablation.

Qbiotics said "none of the 14 completely ablated tumors recurred at six months, indicating tigilanol tiglate may provide durable responses".

The company said 11 patients were administered 0.5 milligrams of tigilanol tiglate per cubic centimetre of tumor volume to one or more of their tumors, with 10 patients included in the response evaluable population as they had a tumor assessment at both baseline and at 28 days post-treatment.

Qbiotics said one patient did not attend the follow-up and was excluded from the data.

In 2023, Qbiotics said it had treated the first of 10 patients in its open-label, single-arm, preliminary efficacy trial of intra-tumoral tigilanol tiglate for soft tissue sarcoma in the US (BD: Jun 13, 2023).

At that time, the company said tigilanol tiglate was "a small molecule targeting a range of solid tumors" and that the drug was registered and marketed as a cancer drug for animals under the trade name Stelfonta, in the US, Europe, the UK and Australia.

In 2024, Qbiotics said the trial showed tigilanol tiglate had exceeded "the primary endpoint for a promising response" and was safe (BD: Sep 17, Nov 19, 2024)

Earlier this year, the company said further data from the trial showed tigilanol tiglate had "rapid systemic clearance after intra-tumoral injection" (BD: Feb 17, 2025).

Today, Qbiotics said all 11 treated patients were included in the safety evaluation and that the tigilanol tiglate was well tolerated, with most of the adverse events "expected and related to the local action of the drug" such as local pain, swelling, necrosis.

The company said that "the absence of tumor recurrence in cases achieving a complete response further underscores tigilanol tiglate's potential as an effective treatment option for soft tissue sarcomas and possibly other solid tumors".

Qbiotics said that the results to date supported the progression of a trial expansion, which would further investigate the clinical utility and therapeutic potential of tigilanol tiglate in patients with soft tissue sarcoma at New York's Memorial Sloan Kettering Cancer Center.

According to the US National Library of Medicine Clinical Trials website, the expansion trial was expected to dose up-to 40 evaluable patients with a maximum of three treatments seven days apart.

Qbiotics managing-director Stephen Doyle said the company was "delighted with the outcomes from stage one of our phase IIa soft tissue sarcoma trial".

"Tigilanol tiglate met both its primary and secondary endpoints and delivered patients an impressive 80 percent objective response rate in injected tumors," Mr Doyle said.

"Importantly, none of the 14 fully-ablated (destroyed) tumors had recurred by the six-month follow-up period, suggesting tigilanol tiglate may provide long-term benefit for patients," Mr Doyle said.

"Given soft tissue sarcoma is a challenging cancer to treat, achieving this level of clinical activity is highly encouraging," Mr Doyle said. "[And] given the positive results from stage one of the trial, and compelling investigator reports that tigilanol tiglate may improve responses to systemic therapies in metastatic [soft tissue sarcoma] we have moved ahead with the expansion arm of the study, announced late last year."

Qbiotics is a public-unlisted company.

SNOW CENTRE FOR IMMUNE HEALTH
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Snow Centre says it will partner with Glasgow, Scotland's Aridhia and Melbourne's Biogrid Australia for a digital system to support its immunology clinical research.
In 2023, WEHI said the Snow Medical Research Foundation would invest $10 million a year for 10-years to open an immunology research centre (BD: Nov 20, 2023).
At that time, WEHI said it would run the Snow Centre for Immune Health with the Royal Melbourne Hospital and bring researchers to "transform how we research and treat the immune system" and translate laboratory discoveries to benefit patients.
The Snow Centre said Aridhia would provide its internet-based 'digital research environment' that allowed "Australian researchers to work seamlessly with national and international partners in real-time".
The Centre said the "innovative, purpose-built research environment provides secure storage to easily access, share and analyze research and clinical data obtained from study patients in an integrated manner".
The Snow Centre said Aridhia's research environment offered support "for a wide variety of multi-modal data types including clinical data from electronic medical records, medical imaging, and genomic data using common data models".
The Centre said Biogrid would provide a system "to securely house the data and support the Snow Centre with the ethics and governance framework needed to facilitate responsible, compliant data sharing, enabling faster implementation of programs for researchers and protecting patient privacy".
The Snow Centre said the partnership would allow its researchers "to securely access and collaborate on patient samples, such as blood and saliva, and associated research data, all from a single, secure hub".
The Centre said the platform would support its "goals to deliver earlier diagnoses, better treatments and improved outcomes for patients … with debilitating immune conditions".
Snow Centre chief consulting scientist Dr Paul Lyons said the partnership provided "the tools to tackle some of the most complex and devastating immune diseases with a truly integrated approach".
"This isn't just technology, it's a tool for change," Dr Lyons said.

CLEO DIAGNOSTICS

Cleo says it has approval to use cancer blood samples from the US National Cancer Institute's bio-bank to generate data for its ovarian cancer pre-surgical screening test.
Cleo said the data would be used to support its US Food and Drug Administration 510(k) submission and to "accelerate development and commercialization of its screening test".
The company said the data would "strengthen the evidence package supporting Cleo's FDA submission, and significantly de-risks key regulatory milestones".
Cleo said the US National Cancer Institute's prostate, lung, colorectal and ovarian cancer screening trial bio-bank included more than 155,000 participants over a decade and contained "extensively annotated, rigorously collected biospecimens, offering a gold-standard resource for the development of early cancer detection technologies".
The company said recruitment for its US clinical trials were ongoing, with completion expected by 2026.
Last year, Cleo said it had recruited the first of "a minimum of 500 patients" in a 10-month, US trial of its ovarian cancer blood test conducted with New York contract research organization Lindus Health for an FDA 510(k) application (BD: Sep 6, 2024).
Cleo was up three cents or 8.8 percent to 37 cents.

BLUECHIIP

Bluechiip administrator Romanis Cant says a creditors meeting will vote on whether the administration should end or whether the company should be wound up.
The administrators said no deed of company arrangement had been received and that the meeting would vote on whether the Bluechiip should enter liquidation or whether the administration should end and control of the company be returned to its directors.
The administrators said the meeting would vote on its remuneration for services rendered and that a “committee of inspection not be formed”.
Last year, the ASX said it had suspended Bluechiip under Listing Rule 17.5 for “not lodging the relevant period report by the due date” (BD: Oct 1, 2024).
In March, the company said it appointed Romanis Cant’s Manuel Hanna as its voluntary administrator and that he would undertake “an assessment of the company’s business operations and financial affairs” (BD: Mar 18, 2025).
The meeting will be held virtually, on July 4, 2025 at 11am (AEST).
Bluechiip last traded at 0.3 cents.

PERCHERON

Percheron has requested a trading halt “pending an announcement in relation to a licencing transaction”.
Earlier this year, Percheron said that it had submitted a non-binding proposal to an “international pharmaceutical company” to licence a drug program for a “rare neurological disease” (BD: Feb 24, 2025).
Trading will resume on June 27, 2025, or on an earlier announcement.
Percheron last traded at one cent.

BLINKLAB

Blinklab has told the ASX that it is not aware of any information it has not announced which, if known, could explain the recent trading in its securities.
The ASX said the company’s share price rose 13.6 percent from a low of 44 cents at the close of trading on June 23, 2025 to a high of 50 cents yesterday and noted a “significant increase” in the volume of securities traded.
Blinklab said that at the date of the letter, the results on its attention deficit hyperactivity disorder diagnostic which were expected to be available by June 30, 2025 were “not yet available” and it would provide an update when the information was available.
Blinklab fell half a cent or one percent to 49 cents.

OSTEOPORE

Advance Opportunities Fund says it has reduced its substantial shareholding in Osteopore from 15,096,074 shares (8.25%) to 13,096,074 shares (7.15%).
The Cayman Islands-based Advance said that it sold 2,000,000 shares on June 24, 2025 for $22,000, or 1.1 cents a share.
Last year, Osteopore said that it expected to raise $20 million from Advance for a redeemable convertible note at four percent interest a year, issuing in four equal tranches of 20 equal sub-tranches of $250,000 each, converting at 80 percent of the average closing price on “any five consecutive business days” as selected by the noteholder during the 45 business days immediately preceding the conversion date (BD: Sep 27, 2024).
Osteopore was up 0.1 cents or 10 percent to 1.1 cents.

AVECHO BIOTECHNOLOGY

Mark Kerr and associates say their substantial shareholding of 349,133,188 shares in Avecho has been diluted from 11.52 percent to 11.00 percent.
Avecho was unchanged at 0.4 cents with 2.4 million shares traded.

NYRADA

Nyrada says Mark Azzi has increased his substantial shareholding from 27,510,404 Chess depository interests (CDIs) (13.04%) to 30,427,243 CDIs (14.43%).
Nyrada was up one cent or 4.55 percent to 23 cents.

MACH7 TECHNOLOGIES

Mach7 says it has appointed Naomi Lawrie as company secretary to replace corporate compliance services firm Vistra Australia's Tony Panther, effective from June 24, 2025.
Mach7 said Ms Lawrie had more than 20 years of experience and had been 4D Medical's general counsel and company secretary.
Mach7 was up half a cent or 1.5 percent to 34.5 cents.